Clinical Trial Update: Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating daratumumab plus pomalidomide in previously treated AL amyloidosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Daratumumab (daratumumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: AL Amyloidosis | Phase 2 | Status: TERMINATED